Table 1.
Patient Characteristics at Enrolment (n=67,686)
| Variables | n (%) |
|---|---|
| Age at enrollment (yrs),% | |
| <25 | 6,398(9.5) |
| 25–<35 | 27,609(40.8) |
| 35–<45 | 22,157(32.7) |
| 45+ | 11,497(17.0) |
| Male sex, % | 17,053(25.2) |
| Family size >3 members, % | 8,615(14.6) |
| District of Dar es Salaam,% | |
| Ilala | 26,784(39.6) |
| Kinondoni | 22,979(34.0) |
| Temeke | 17,803(26.4) |
| Year of enrolment,% | |
| 2004 or 2005 | 3,658(5.4) |
| 2006 | 7,349(10.9) |
| 2007 | 10,279(15.2) |
| 2008 | 11,577(17.1) |
| 2009 | 11,068(16.3) |
| 2010 | 9,419(13.9) |
| 2011 | 8,101(2.0) |
| 2012 | 6,235(9.2) |
| Season of enrollment,% | |
| Dec.–Mar. (Short dry) | 21,784(32.2%) |
| Apr.–May (Long rainy) | 10,835(16.0) |
| Jun.–Sept. (Long dry) | 23,895(35.3) |
| Oct.–Nov. (Short rainy) | 111,72(16.5) |
| BMI at enrollment (kg/m2),% | |
| <17 | 6,332(10.2) |
| 17–<18.5 | 6749(10.9) |
| 18.5–<25.0 | 33,784(54.7) |
| 25–<30.0 | 10,627(17.2) |
| 30.0+ | 4,321(7.0) |
| MUAC at enrollment (cm),% | |
| <20 | 2,581(4.6) |
| 20–<22 | 5,137(9.1) |
| 22–<25 | 15,771(28.1) |
| 25–<27 | 12,061(21.4) |
| 27+ | 20,671(36.8) |
| Anemia status,% | |
| Severe anemia | 5,614(12.7) |
| Moderate anemia | 19,796(44.8) |
| Mild anemia | 9,292(21.0) |
| Non-anemia | 9,467(21.4) |
| CD4+ cell counts at enrolment (cells/uL) | |
| <50 | 8,643(15.6) |
| 50–<100 | 6,346(11.4) |
| 100–<200 | 11,449(20.6) |
| 200–<350 | 13,297(23.9) |
| 350+ | 15,836(28.5) |
| WHO Stage at enrollment,% | |
| I | 17,627(26.6) |
| II | 14,941(22.6) |
| III | 25,138(38.0) |
| IV | 8,478(12.8) |
| ALT>40u/L at enrolment, % | 4,832(11.3) |
| Cotrimoxazole use at enrollment, % | 21,087(33.2) |
| ART regimensa | |
| D4T+3TC+NVP | 13,816(37.7) |
| AZT+3TC+NVP | 5,965(16.3) |
| TDF+FTC+NVP | 32(0.1) |
| D4T+3TC+EFV | 2,489(6.8) |
| AZT+3TC+EFV | 13,351(36.5) |
| TDF+FTC+EFV | 940(2.6) |
Values are means (standard deviation) unless specified;
Notes: BMI, body mass index; MUAC, middle upper arm circumference; ALT, alanine aminotransferase; ART, antiretroviral therapy.
a
Distribution of ART regimens among patients who started ART during the follow-up. (d4T, stavudine; AZT, zidovudine; TDF, tenofovir; EFV, efavirenz; NVP, nevirapine; 3TC, lamivudine; FTC, emtricitabine)